Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol is a synthetic small molecule belonging to the class of phenol ethers and benzenoids. It features a morpholine ring and a dimethyl-substituted phenoxy group attached to a propanol backbone. The compound has been structurally characterized in complex with beta-secretase 1 (BACE1), suggesting it may act as an inhibitor of this enzyme. BACE1 is involved in the cleavage of amyloid precursor protein and is implicated in Alzheimer's disease pathology. However, there are no known approved clinical uses or marketed products containing this compound as an active ingredient[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol.